US 2004/0067216 Al  38  Apr. 8, 2004  OSC size capsules (Capsugelfi, Warner-Lambert), which  were then closed. Four Beagle dogs were dosed orally with  the capsules which provided 10 mg of Compound A per kg  of body weight (mpk) followed by 5 mL/kg of water. The  dogs were pre-acidified with a subcutaneous injection of  pentagastrin about 10 to 15 minutes prior to dosing the  capsules. The dose of pentagastrin was variable due to  adverse reactions in the dogs, but each dog received enough  pentagastrin to lower the stomach pH. The same dogs were  also dosed orally with a control capsule.  [0422]  The same dogs (without pre-acidification) were  also orally dosed with 10 mpk of (i) Compound  A  dissolved  in propylene glycol-HCl-ethanol (98:2:5) and (ii) Com› pound A in an encapsulated polyethylene glycol-HCl gel.  For each dosing run, blood samples were drawn from  catheters placed in the cephalic vein at pre-dose at 0, 0.333,  0.5, 0.67, 1, 2, 4, 6, 8 and 24 hours after dosing. The sample  extracts were extracted via a liquid-liquid extraction proce› dure employing methyl t-butyl ether to isolate Compound  A  from the biological mixture/plasma. Indinavir was used as  the internal standard. The sample extracts were analyzed by  LC/MS/MS  in the positive ion mode using an electrospray  interface. The area under the curve (AUC) was calculated by  linear trapezoidal rule from observed data points using  Microsoft Excel 97 SR-2. Arithmetic mean and standard  error of the mean (SEM) for AUC, observed maximum  plasma concentration (Cmax), and time of Cmax (Tmax) were  calculated with Microsoft Excel v 97 SR-2. The results are  shown in Tables 2, 3 and 4 below.  [0425]  Tables 2-4 show that the Compound A-resin com› plex with pre-acidification has a pharmacokinetic profile  similar to that of the glycol solution and the polyglycol gel  capsule. An advantage of the resin complex over the solution  and the gel formulations is that it is a solid which can  facilitate handling and administration. Another advantage is  that the resin complex is more stable thermally. Thermal  stability studies conducted at 25°  C. and 40°  C. on these  three formulations have indicated that the Compound  A-resin complex has little or no growth of degradates (e.g.,  lactones) relative to the solution and gel formulations. The  resin complex does require an acidic stomach in order to  release the drug, but this can routinely and easily be accom› plished by administering the complex to the subject after a  meal or with a carbonated beverage.  [0426]  While the foregoing specification teaches the prin› ciples of the present invention, with examples provided for  the purpose of illustration, the practice of the invention  encompasses all of the usual variations, adaptations and/or  modifications that come within the scope of the following  claims.  What is claimed is:  1.  A pharmaceutical composition which comprises a cat› ion exchange resin complexed with a compound of Formula  (I)  or a pharmaceutically acceptable salt thereof:  wherein  TABLE  2  TABLE  3  [0423]  Tw,, (hr)  Resin Complex  Resin Capsule  Glycol  Polyglycol  Capsule  Control  Solution  Capsule  Dog 1  1.00  1.00  0.50  0.50  Dog 2  1.00  0.75  0.25  0.50  Dog 3  1.00  1.00  0.25  1.00  Dog 4  1.00  0.50  0.50  0.75  Mean  1.00  0.81  0.38  0.69  SEM  0.00  0.12  0.07  0.12  AUC$_{0}$_$_{24 }$hrs (µM • hr)  Resin Complex  Resin Capsule  Glycol  Polyglycol  Capsule  Control  Solution  Capsule  Dog 1  0.4735  0.0156  0.8245  1.523  Dog 2  0.1614  0.2022  0.1364  0.305  Dog 3  0.2884  0.0218  0.0536  0.055  Dog 4  0.7104  0.0601  0.3788  0.217  Mean  0.4084  0.0749  0.3483  0.5251  SEM  0.1193  0.0436  0.1731  0.3367  Cw,, (gM)  Resin Complex  Resin Capsule  Glycol  Polyglycol  Capsule  Control  Solution  Capsule  Dog 1  0.258  0.0071  0.595  1.32  Dog 2  0.0975  0.142  0.115  0.275  Dog 3  0.244  0.0126  0.0729  0.031  Dog 4  0.513  0.062  0.435  0.144  Mean  0.278  0.056  0.305  0.444  SEM  0.086  0.031  0.126  0.298  R  1  is C$_{1 }$-C$_{6 }$ alkyl, C$_{2}$-C$_{6 }$ alkenyl, C$_{2}$ -C$_{6 }$ alkynyl, C$_{3}$ -C$_{6 }$ cycloalkyl, aryl, substituted aryl, heteroaryl, or substi› tuted heteroaryl; wherein  (I)  (i) each of the substituents on substituted aryl is inde› pendently  (a) halogen,  (b) cyano,  TABLE  4  [0424] 